JX Advanced Metals
5016
Timee
215A
Nippon Telegraph & Telephone
9432
4
Metaplanet
3350
5
The Why How Do
3823
JP Stock MarketDetailed Quotes
4503 Astellas Pharma
- 1502.5
- +2.5+0.17%
20min DelayTrading Mar 26 09:50 JST
2.72TMarket Cap158.66P/E (Static)
1512.5High1497.5Low1.37MVolume1510.0Open1500.0Pre Close2.06BTurnover1835.052wk High0.08%Turnover Ratio1.81BShares1415.052wk Low-32.04EPS TTM2.60TFloat Cap2360.5Historical High158.66P/E (Static)1.73BShs Float540.0Historical Low9.47EPS LYR1.00%Amplitude72.00Dividend TTM1.80P/B100Lot Size4.79%Div YieldTTM
Astellas Pharma News
Astellas Pharma: Extraordinary Report
Astellas Pharma: Extraordinary Report
Astellas Pharma: Financial results briefing materials for the 3rd quarter of the fiscal year ending March 31, 2025
Astellas Pharma: Supplemental financial results for the 3rd quarter of the fiscal year ending March 31, 2025
Astellas Pharma: Summary of financial results for the 3rd quarter of the fiscal year ending March 31, 2025 [IFRS] (consolidated)
Astellas Pharma: Progress in core business, recording impairment losses, and revisions to full-year earnings forecasts
Astellas Pharma: Confirmation letter
Astellas Pharma: Half Year Report - Term 20 (2024/04/01 - 2025/03/31)
Astellas Pharma: Supplementary financial information for the 2nd quarter (interim period) of the fiscal year ending March 31, 2025
Astellas Pharma: Financial results briefing materials for the 2nd quarter (interim period) of the fiscal year ending March 31, 2025
Astellas Pharma: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [IFRS] (consolidated)
Astellas Pharma: Earnings conference materials for Q1 of the fiscal year ending March 2025.
Astellas Pharma: Supplemental materials for the first quarter financial statements of March 2025.
Astellas Pharma: March 2025 first quarter financial results announcement [IFRS] (consolidated)
Astellas Pharma: Extraordinary Report
Astellas Pharma: Confirmation letter
Astellas Pharma: Securities Report - 19th Period (April 1, 2023 - March 31, 2024)
Astellas Pharma: Financial results briefing materials for the fiscal year ending March 2024
Astellas Pharma: Supplemental Financial Results for the Fiscal Year Ending March 2024
Astellas Pharma: Summary of financial results for the fiscal year ending March 31, 2024 [IFRS] (consolidated)